{"id":2769,"date":"2025-12-08T14:21:01","date_gmt":"2025-12-08T14:21:01","guid":{"rendered":"https:\/\/www.arcgroup.io\/oxford\/?p=2769"},"modified":"2025-12-08T16:28:56","modified_gmt":"2025-12-08T16:28:56","slug":"accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/","title":{"rendered":"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_073e19ebdd4413afa35b473448a27bad\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png 632w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT-300x165.png 300w\" type=\"image\/png\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n            <\/ul>\n\n\n\n<p>ARC Oxford based <a href=\"https:\/\/www.accessiontherapeutics.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Accession Therapeutics<\/a>, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, has announced \u00a330.5 million raised from its existing investors.<\/p>\n\n\n\n<p>Accession Therapeutics\u2019 tumour-targeted immunotherapy platform, <a href=\"https:\/\/www.accessiontherapeutics.com\/trocept\" target=\"_blank\" rel=\"noreferrer noopener\">TROCEPT<\/a>, is designed to activate the immune system in solid tumours that are resistant to conventional treatment. By combining targeted viral delivery with localised immune activation only in tumours, TROCEPT offers a potent, selective and scalable approach.<\/p>\n\n\n\n<p>Proceeds from the financing will be used to advance Accession Therapeutics\u2019 growing pipeline of first-in-class immunotherapies developed using the platform. This includes enabling the Company to generate full clinical data from its ongoing Phase 1 ATTEST study of TROCEPT-01 (ATTR-01), the Company\u2019s lead programme designed to selectively generate a clinically validated checkpoint inhibitor within advanced solid tumours. Funds will also be used to progress TROCEPT-02 into the clinic.&nbsp; This second programme is designed to deliver a proprietary genetically encoded universal bispecific T cell engager into tumours.<\/p>\n\n\n\n<p><strong>Bent Jakobsen, PhD FMedSci, Chief Executive Officer of Accession Therapeutics<\/strong>, said: \u201cThis financing reflects the continued strong support of our investors and enables us to take the next important steps in advancing the TROCEPT pipeline. With TROCEPT-01 now in the clinic, and TROCEPT-02 following close behind, we are building momentum towards demonstrating the potential of our tumour-targeted immunotherapy platform.\u201d<\/p>\n\n\n\n<p><strong>Jeff Lin, Partner of iGlobe Partners<\/strong>, said: \u201cWe are proud to continue supporting Accession Therapeutics as it advances its innovative TROCEPT platform into the clinic. The company has made remarkable progress in a short period of time, and we believe TROCEPT has the potential to create a new class of immunotherapies for patients with solid tumours.\u201d<\/p>\n\n\n\n<p>Since inception in 2021, the Company has raised nearly USD $100 million from high-net-worth individuals and venture capitalists, including iGlobe Partners, Primavera Venture Partners and Birk Ventures.<\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n    <section class=\"news-archive \" id=\"block_4d74a757aea1113b21cda480ac069f25\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png 1200w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-300x169.png 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1024x576.png 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-768x432.png 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1000x563.png 1000w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-475x267.png 475w\" type=\"image\/png\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\" target=\"_self\">\n\t\t\t\tAccession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg 1110w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-300x201.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1024x685.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-768x513.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1000x668.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\" target=\"_self\">\n\t\t\t\tChildbase Partnership announces new Garsington Road day nursery opening at ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg 2402w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-300x200.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1024x682.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-768x512.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1000x666.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\" target=\"_self\">\n\t\t\t\tOxa Raises $103m in Series D First Close to supercharge Industrial Mobility Automation\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>ARC Oxford based Accession Therapeutics, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, has announced \u00a330.5 million raised from its existing investors. Accession Therapeutics\u2019 tumour-targeted immunotherapy platform, TROCEPT, is designed to activate the immune system in solid tumours that are resistant to conventional treatment. By combining targeted viral delivery with localised immune activation only [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":2770,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22],"tags":[6210,50841],"class_list":["post-2769","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-life-science-and-health","tag-member-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform - ARC Oxford<\/title>\n<meta name=\"description\" content=\"ARC Oxford based Accession Therapeutics, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, has announced \u00a330.5 million raised from its existing investors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform - ARC Oxford\" \/>\n<meta property=\"og:description\" content=\"ARC Oxford based Accession Therapeutics, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, has announced \u00a330.5 million raised from its existing investors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Oxford\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T14:21:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-08T16:28:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png\" \/>\n\t<meta property=\"og:image:width\" content=\"632\" \/>\n\t<meta property=\"og:image:height\" content=\"348\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"nataliegelder\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"nataliegelder\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/\"},\"author\":{\"name\":\"nataliegelder\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3\"},\"headline\":\"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform\",\"datePublished\":\"2025-12-08T14:21:01+00:00\",\"dateModified\":\"2025-12-08T16:28:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/\"},\"wordCount\":300,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png\",\"keywords\":[\"Life science and Health\",\"Member news\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/\",\"name\":\"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform - ARC Oxford\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png\",\"datePublished\":\"2025-12-08T14:21:01+00:00\",\"dateModified\":\"2025-12-08T16:28:56+00:00\",\"description\":\"ARC Oxford based Accession Therapeutics, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, has announced \u00a330.5 million raised from its existing investors.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png\",\"width\":632,\"height\":348,\"caption\":\"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/oxford\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"name\":\"ARC Oxford\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"alternateName\":\"ARC Oxford\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\",\"name\":\"ARC Oxford\",\"alternateName\":\"ARC Oxford\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"width\":2084,\"height\":2084,\"caption\":\"ARC Oxford\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3\",\"name\":\"nataliegelder\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g\",\"caption\":\"nataliegelder\"},\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/nataliegelder\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform - ARC Oxford","description":"ARC Oxford based Accession Therapeutics, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, has announced \u00a330.5 million raised from its existing investors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/","og_locale":"en_US","og_type":"article","og_title":"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform - ARC Oxford","og_description":"ARC Oxford based Accession Therapeutics, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, has announced \u00a330.5 million raised from its existing investors.","og_url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/","og_site_name":"ARC Oxford","article_published_time":"2025-12-08T14:21:01+00:00","article_modified_time":"2025-12-08T16:28:56+00:00","og_image":[{"width":632,"height":348,"url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png","type":"image\/png"}],"author":"nataliegelder","twitter_card":"summary_large_image","twitter_misc":{"Written by":"nataliegelder","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/"},"author":{"name":"nataliegelder","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3"},"headline":"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform","datePublished":"2025-12-08T14:21:01+00:00","dateModified":"2025-12-08T16:28:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/"},"wordCount":300,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png","keywords":["Life science and Health","Member news"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/","url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/","name":"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform - ARC Oxford","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png","datePublished":"2025-12-08T14:21:01+00:00","dateModified":"2025-12-08T16:28:56+00:00","description":"ARC Oxford based Accession Therapeutics, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, has announced \u00a330.5 million raised from its existing investors.","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#primaryimage","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/12\/Accession-Therapeutics-TROCEPT.png","width":632,"height":348,"caption":"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform"},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2025\/12\/08\/accession-therapeutics-raises-30-5-million-to-advance-trocept-immunotherapy-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/oxford\/"},{"@type":"ListItem","position":2,"name":"Accession Therapeutics raises \u00a330.5 million to advance TROCEPT immunotherapy platform"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/oxford\/#website","url":"https:\/\/www.arcgroup.io\/oxford\/","name":"ARC Oxford","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"alternateName":"ARC Oxford","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/oxford\/#organization","name":"ARC Oxford","alternateName":"ARC Oxford","url":"https:\/\/www.arcgroup.io\/oxford\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","width":2084,"height":2084,"caption":"ARC Oxford"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3","name":"nataliegelder","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g","caption":"nataliegelder"},"url":"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/nataliegelder\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/2769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/comments?post=2769"}],"version-history":[{"count":0,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/2769\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media\/2770"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media?parent=2769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/categories?post=2769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/tags?post=2769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}